Study the Anti-MUC1 antibody-based iron oxide nanoparticles on three-dimension spheroid and breast cancer (MCF-7) cell imaging

Pegah Moradi Khaniabadi 1 , Daryoush Shahbazi-Gahrouei 2 , Amin Malik Shah Abdul Majid 3 , and Bita Moradi Khaniabadi 4
  • 1 School of Physics, Universiti Sains Malaysia, 11800, Malaysia
  • 2 Dept. of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan
  • 3 School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Malaysia
  • 4 Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan


Non-invasive methods for breast cancer detection in early stages may help to increase the survival rate of patients. This study aimed to evaluate the application of Anti-MUC1 antibody-based iron oxide nanoparticle (SPIONs-C595) which was assessed in vivo as a molecular imaging probe for breast cancer (MCF-7) detection using MRI. Nine groups of female NRC NU/Nu mice (each group of 3), 6 to 8 weeks old were used and MCF-7 cells were injected subcutaneously into both flanks of nude mice. After two weeks the mice received an intravenous injection of different concentrations of SPIONs-C595. The uptake ability of SPIONs-C595 on three-dimension (3D) macrostructure is exploited a modified hanging drop method using Prussian blue for MCF-7 cells. The iron content was measured in liver, kidney, spleen, and tumor. The MR imaging features and biodistribution of nanoprobe was also investigated. The MR images obtained from digested tumor after nanoprobe administration in different time-period revealed that enhancement of T1 and T2 relaxation time. Moreover, the storage stability test was shown great application and no sedimentation of nanoparticles within two months storage at 4°C. Additionally, great validation of SPIONs-C595 on the 3D spheroid of MCF-7 was observed. The biodistribution analysis showed that iron content of the spleen was more than the other studied organs. These results highlighted the feasibility of an in-vivo model for detection of breast cancer MUC1 expression. Current researches are ongoing to further enhancement of relaxation times for classification of MUC1 status using clinical specimens.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] de Rooij M, Hamoen EH, Fütterer JJ, et al., Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. American Journal of Roentgenology. 2014;202(2):343-351.

  • [2] Shahbazi-Gahrouei D. Novel MR imaging contrast agents for cancer detection. Journal of Research in Medical Sciences. 2009;14(3):141-147.

  • [3] Shahbazi-Gahrouei D, Rizvi S, Williams M, Allen BJ. In vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents. Australasian Physics & Engineering Sciences in Medicine. 2002;25(1):31-38.

  • [4] Padmanabhan P, Kumar A, Kumar S, et al. Nanoparticles in practice for molecular-imaging applications: An overview. Acta Biomaterialia. 2016;41:1-16.

  • [5] Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ. In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: Potential magnetic resonance imaging contrast agents for melanoma. Journal of Magnetic Resonance Imaging. 2001;14(2):169-174.

  • [6] Abdolahi M, Shahbazi-Gahrouei D, Laurent S, et al. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media and Molecular Imaging, 2013;8(2):175-184.

  • [7] Mirzaei M, Mohagheghi M, Shahbazi-Gahrouei D, Khatami A. Novel nanosized Gd3+-ALGD-G2-C595: in vivo dual selective MUC-1 positive tumor molecular MR imaging and therapeutic agent. J Nanomed Nanotechnol. 2012;3(7):147-152.

  • [8] Shahbazi-Gahrouei D, Williams M, Allen B. In vitro study of relationship between signal intensity and gadolinium-DTPA concentration at high magnetic field strength. Australasian Radiology. 2001;45(3):298-304.

  • [9] Shahbazi-Gahrouei D, Abdolahi M. A novel method for quantitative analysis of anti-MUC1 expressing ovarian cancer cell surface based on magnetic cell separation. Journal of Medical Sciences. 2012;12(8):256-266.

  • [10] Shahbazi-Gahrouei D, Abdolahi M. Superparamagnetic iron oxide-C595: Potential MR imaging contrast agents for ovarian cancer detection. Journal of Medical Physics. 2013;38(4):198-204.

  • [11] Shahbazi-Gahrouei D, Abdolahi M. Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging. The Scientific World Journal. 2013;2013:609151.

  • [12] Ghasemian Z, Shahbazi-Gahrouei D, Manouchehri S. Cobalt zinc ferrite nanoparticles as a potential magnetic resonance imaging agent: An in vitro study. Avicenna Journal of Medical Biotechnology. 2015;7(2):64-68.

  • [13] Zahraei M, Marciello M, Lazaro-Carrillo A, et al. Versatile theranostics agents designed by coating ferrite nanoparticles with biocompatible polymers. Nanotechnology. 2016;27(25):255702.

  • [14] Zahraei M, Monshi A, del Puerto Morales M, et al. Hydrothermal synthesis of fine stabilized superparamagnetic nanoparticles of Zn2+ substituted manganese ferrite. Journal of Magnetism and Magnetic Materials. 2015;393:429-436.

  • [15] Hattrup L, Gendler J. MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Research. 2006;8(4):R37.

  • [16] Wang L, Ma J, Liu F, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecologic Oncology. 2007;105(3):695-702.

  • [17] Boult K, Borri M, Jury A, et al. Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging. NMR in Biomedicine. 2016;29(11):1608-1617.

  • [18] Danhier P, Magat J, Levêque P, et al. In vivo visualization and ex vivo quantification of murine breast cancer cells in the mouse brain using MRI cell tracking and electron paramagnetic resonance. NMR in Biomedicine. 2015;28(3):367-375.

  • [19] Estelrich J, Sánchez-Martín J, Busquets A. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. International Journal of Nanomedicine. 2015;10:1727-1741.

  • [20] Seyfer P, Pagenstcher A, Mandic R, et al. Cancer and inflammation: Differentiation by USPIO-enhanced MR imaging. Journal of Magnetic Resonance Imaging. 2014;39(3):665-672.

  • [21] Neuwelt A, Sidhu N, Hu C, et al. Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation. American Journal of Roentgenology. 2015;204(3):W302-W313.

  • [22] Kandasamy G, Maity D. Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics. International Journal of Pharmaceutics. 2015;496(2):191-218.

  • [23] Vidavsky N, Kunitake A, Chiou E, et al. Studying biomineralization pathways in a 3D culture model of breast cancer microcalcifications. Biomaterials. 2018;179:71-84.

  • [24] Talari S, Raza A, Rehman S, Rehman IU. Analyzing normal proliferating, hypoxic and necrotic regions of T-47D human breast cancer spheroids using Raman spectroscopy. Applied Spectroscopy Reviews. 2017;52(10):909-924.

  • [25] Khaniabadi M, Majik AMSA; Asif M, et al. Breast cancer cell targeted MR molecular imaging probe: Anti-MUC1 antibody-based magnetic nanoparticles. Journal of Physics: Conference Series. 2017;851:012014.

  • [26] Khaniabadi M, Shahbazi-Gahrouei D, Suhaimi M, et al. In vitro study of SPIONs-C595 as molecular imaging probe for specific breast cancer (MCF-7) cells detection. Iranian Biomedical Journal. 2017;21(6):360-368.

  • [27] Khaniabadi M, Shahbazi-Gahrouei D, Jafaar S, et al. Magnetic iron oxide nanoparticles as T2 MR imaging contrast agent for detection of breast cancer (MCF-7) cell. Avicenna Journal of Medical Biotechnology. 2017;9(4):181-188.

  • [28] Jafari F, Khadeer B, Iqbal A, et al. Increased aqueous solubility and proapoptotic activity of potassium koetjapate against human colorectal cancer cells. Journal of Pharmacy and Pharmacology. 2014;66(10):1394-1409.

  • [29] Funovics A, Kapeller B, Hoeller C, et al. MR imaging of the her2/neu and 9.2. 27 tumor antigens using immunospecific contrast agents. Magnetic Resonance Imaging. 2004;22(6):843-850.

  • [30] Oghabian M, Jeddi-Tehrani M, Zolfaghari A, et al. Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI. Journal of Nanoscience and Nanotechnology. 2011;11(6):5340-5344.

  • [31] Arancibia S, Barrientos A, Torrejón J, et al. Copper oxide nanoparticles recruit macrophages and modulate nitric oxide, proinflammatory cytokines and PGE2 production through arginase activation. Nanomedicine. 2016;11(10):1237-1251.

  • [32] Zhang J, Ring L, Hurley R, et al. Quantification and biodistribution of iron oxide nanoparticles in the primary clearance organs of mice using T1 contrast for heating. Magnetic Resonance in Medicine. 2017;78(2):702-712.

  • [33] Rodríguez E, Simoes V, Roig A, et al. An iron-based T 1 contrast agent made of iron-phosphate complexes: In vitro and in vivo studies. Magnetic Resonance Materials in Physics, Biology and Medicine. 2007;20(1):27-37.

  • [34] Callaghan F, Mohammadi S, Weiskopf N. Synthetic quantitative MRI through relaxometry modelling. NMR in Biomedicine. 2016;29(12):1729-1738.


Journal + Issues